Proposed LCD - MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma (DL39585)

Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.JAMA Dermatol. 2013;149(4):402-410. doi:10.1001/jamadermatol.2013.2456Karia PS, Morgan FC, Califano JA, Schmults CD. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC cancer staging manual.JAMA Dermatol. 2018;154(2):175-181. doi:10.1001/jamadermatol.2017.3960Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2021;84(2):361-369. doi:10.1016/j.jaad.2020.04.088Amin MB, Edge S, Green F, et al., eds.AJCC Cancer Staging Manual.8thed. Springer; 2018.Burns C, Kubicki S, Nguyen QB, et al. Advances in cutaneous squamous cell carcinoma management.Cancers (Basel). 2022;14(15):3653.Work Group; Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2018;78(3):560-578. doi:10.1016/j.jaad.2017.10.007Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system.JAMA Dermatol. 2014;150(1):19-24. doi:10.1001/jamadermatol.2013.6675Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature.Dermatol Surg. 2006;32(11):1309-1321. doi:10.1111/j.1524-4725.2006.32300.xDurham AB, Lowe L, Malloy KM, et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck.JAMA Otolaryngol Head Neck Surg. 2016;142(12):1171-1176. doi:10.1001/jamaoto.2016.1927Gore SM, Shaw D, Martin RC, et al. Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck.Head Neck. 2016;38 Suppl 1:E884-E889. doi:10.1002/hed.24120Renzi C, Caggiati A, Mannooranparampil TJ, et al. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature.Eur J Surg Oncol. 2007;33(3):364-369. doi:10.1016/j.ejso.2006.10.017Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature.World J Surg Oncol. 2011;9:80. doi:10.1186/1477-7819-9-80Ahmed MM, Moore BA, Schmalbach CE. Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review.Otolaryngol Head Neck Surg. 2014;150(2):180-187. doi:10.1177/0194599813511949Fukushima S, Masuguchi S, Igata T, et al. Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma.J Dermatol. 2014;41(6):539-541. doi:10.1111/1346-8138.12508Takahashi A, Imafuku S, Nakayama J, Nakaura J, Ito K, Shibayama Y. Sentinel node biopsy for high-risk cutaneous squamous cell carcinoma.Eur J Surg Oncol. 2014;40(10):1256-1262. doi:10.1016/j.ejso.2014.05.009Maruyama H, Tanaka R, Fujisawa Y, Nakamura Y, Ito S, Fujimoto M. Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma.J Dermatol. 2017;44(4):431-437. doi:10.1111/1346-8138.13577Tejera-Vaquerizo A, Garca-Doval I, Llombart B, et al. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma.J Dermatol. 2018;45(7):781-790. doi:10.1111/1346-8138.14342Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology clinical practice guideline.Pract Radiat Oncol. 2020;10(1):8-20. doi:10.1016/j.prro.2019.10.014Farberg AS, Fitzgerald AL, Ibrahim SF, et al. Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC): a narrative review.Dermatol Ther (Heidelb). 2022;12(2):267-284. doi:10.1007/s13555-021-00673-yKamiya S, Kato J, Kamiya T, et al. Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.Asia Pac J Clin Oncol. 2020;16(2):e108-e112. doi:10.1111/ajco.13102Garca-Pedrero JM, Martnez-Camblor P, Diaz-Coto S, et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.J Am Acad Dermatol. 2017;77(3):527-533. doi:10.1016/j.jaad.2017.05.047Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.J Cutan Pathol. 2016;43(8):663-670. doi:10.1111/cup.12728Amoils M, Kim J, Lee C, et al. PD-L1 expression and tumor-infiltrating lymphocytes in high-risk and metastatic cutaneous squamous cell carcinoma.Otolaryngol Head Neck Surg. 2019;160(1):93-99. doi:10.1177/0194599818788057Maly CJ, Cumsky HJL, Costello CM, et al. Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2020;82(4):846-853. doi:10.1016/j.jaad.2019.08.027Cumsky HJL, Costello CM, Zhang N, et al. The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2019;80(3):626-632.e1. doi:10.1016/j.jaad.2018.10.018Chen MK, Cai MY, Luo RZ, et al. Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma.Br J Dermatol. 2015;172(1):111-119. doi:10.1111/bjd.13226Campos MA, Macedo S, Fernandes M, et al. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2019;80(3):660-669.e6. doi:10.1016/j.jaad.2018.08.032Xu R, Cai MY, Luo RZ, Tian X, Han JD, Chen MK. The expression status and prognostic value of xancer stem cell biomarker CD133 in cutaneous squamous cell carcinoma.JAMA Dermatol. 2016;152(3):305-311. doi:10.1001/jamadermatol.2015.3781Piipponen M, Nissinen L, Riihil P, et al. p53-Regulated long noncoding RNA PRECSIT promotes progression of cutaneous squamous cell carcinoma via STAT3 signaling.Am J Pathol. 2020;190(2):503-517. doi:10.1016/j.ajpath.2019.10.019Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma.Hum Pathol. 2008;39(3):344-349. doi:10.1016/j.humpath.2007.07.004Caueto J, Cardeoso E, Garca JL, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma.Br J Dermatol. 2017;176(5):1279-1287. doi:10.1111/bjd.14936Arron ST, Wysong A, Hall MA, et al. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.Laryngoscope Investig Otolaryngol. 2022;7(1):135-144. doi:10.1002/lio2.724Ibrahim SF, Kasprzak JM, Hall MA, et al. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.Future Oncol. 2022;18(7):833-847. doi:10.2217/fon-2021-1277Borman S, Wilkinson J, Meldi-Sholl L, et al. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients.Diagn Pathol. 2022;17(1):32. doi:10.1186/s13000-022-01211-wFarberg AS, Hall MA, Douglas L, et al. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.Curr Med Res Opin. 2020;36(8):1301-1307. doi:10.1080/03007995.2020.1763284Arron ST, Blalock TW, Guenther JM, et al. Clinical considerations for integrating gene expression profiling into cutaneous squamous cell carcinoma management.J Drugs Dermatol. 2021;20(6):5s-s11. doi:10.36849/JDD.2021.6068Au JH, Hooper PB, Fitzgerald AL, Somani AK. Clinical utility of the 40-gene expression profile (40-GEP) test for improved patient management decisions and disease-related outcomes when combined with current clinicopathological risk factors for cutaneous squamous cell carcinoma (cSCC): Case Series.Dermatol Ther (Heidelb). 2022;12(2):591-597. doi:10.1007/s13555-021-00665-yLitchman GH, Fitzgerald AL, Kurley SJ, Cook RW, Rigel DS. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.Curr Med Res Opin. 2020;36(8):1295-1300. doi:10.1080/03007995.2020.176328Rebeca T, Giselle P, Litchman GH, Rigel DS. Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists.J Drugs Dermatol. 2019;18(10):980-984.Saleeby R, Bielinksi K, Fitzgerald A, Siegel J, Ibrahim S. A prospective, multi-center clinical utility study demonstrates that the 40-gene expression profile (40-GEP) test impacts clinical management for Medicare-eligible patients with high-risk cutaneous squamous cell carcinoma (cSCC).SKIN The Journal of Cutaneous Medicine.2022;6(6):482-496.